S

Scholar Rock Holding Corp
D

SRRK

44.900
USD
0.10
(0.22%)
Market Open
Volume
11,808
EPS
-3
Div Yield
-
P/E
-19
Market Cap
4,203,311,300
Related Instruments
    C
    CHWY
    0.775
    (2.30%)
    34.510 USD
    F
    FATE
    -0.07500
    (-4.44%)
    1.61500 USD
    G
    GH
    -0.400
    (-1.26%)
    31.270 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    P
    PSTG
    -0.180
    (-0.28%)
    64.220 USD
    R
    RDFN
    0.07000
    (0.82%)
    8.59000 USD
    R
    RGEN
    -0.770
    (-0.53%)
    143.800 USD
    T
    TDOC
    -0.18000
    (-1.90%)
    9.27000 USD
    T
    TWST
    0.150
    (0.31%)
    48.140 USD
    More
News

Title: Scholar Rock Holding Corp

Sector: Healthcare
Industry: Biotechnology
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.